TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01150097
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
Study: NCT00610688
Drug: Prenatal Vitamin
Normalized name: Prenatal Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
Study: NCT01063023
Drug: Ortho Tri-Cyclen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 1 Tablet, once daily
Study: NCT00955396
Drug: GSK1014802
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT00955396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT00992459
Drug: HPN-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
Study: NCT01236768
Drug: AG200-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period.
Study: NCT02717052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
Study: NCT00939848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg od (continuous dosing) until evidence of disease progression has been confirmed
Study: NCT04370782
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
Study: NCT04370782
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 220mg once daily for 5 days
Study: NCT04370782
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 200 mg once daily for 5 days
Study: NCT03921684
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m2 orally twice-daily, 5 days a week for a total of 28 days, given with radiation therapy
Study: NCT03921684
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and fluorouracil 400 mg/m2 IV, fluorouracil 2400 mg/m2 IV (a 46 hrs CI), day 1 of each treatment cycle, every 2 weeks, given with nivolumab
Study: NCT01909986
Drug: [14C]ONO-4053
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose \[14C\]ONO-4053
Study: NCT00111891
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03321539
Drug: CCRT+GP
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.
Study: NCT00565708
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant Therapy
Study: NCT04591301
Drug: HEC113995 PA•H2O tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
Study: NCT04591301
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
Study: NCT00725829
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg/d
Study: NCT00725829
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00996372
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be randomized to flibanserin or placebo in a double-blind manner
Study: NCT02422121
Drug: RNS60
Normalized name: Ronasin 60
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02422121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01085279
Drug: Modified Kligman's formula (Triple topical therapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
Study: NCT03167775
Drug: Elemene Injection/Elemene Oral Emulusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01777776
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
Study: NCT01777776
Drug: LGX818
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
Study: NCT00650845
Drug: Dotarem®-enhanced MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV administration before MRI exam
Study: NCT01859312
Drug: Hydrocortisone (Solucortef)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA). Total daily hydrocortisone dose was calculated based on the patient's estimated cortisol clearance. Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range.
Study: NCT02046616
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
Study: NCT02046616
Drug: Non-Biologic DMARDs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
Study: NCT00791752
Drug: AZD4017
Approvals — FDA: no, EMA: no, PMDA: no
Description: ascending single doses (start dose 2 mg), oral suspension
Study: NCT00791752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03944512
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg Pravastatin taken daily
Study: NCT00389129
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00680472
Drug: HKT-500 Ketoprofen Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: HKT-500 Ketoprofen Topical Patch
Study: NCT00671476
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02945267
Drug: Placebo plus S1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
Study: NCT03803449
Drug: 50ug fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: participants in fentanyl group are given intervention regimen: 50ug fentanyl.
Study: NCT01156116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo tablet
Study: NCT00843193
Drug: INTRAVENOUS GSK679586
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
Study: NCT00843193
Drug: INTRAVENOUS PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
Study: NCT01975376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
Study: NCT00927212
Drug: AS101 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily topical application
Study: NCT00932321
Drug: Norethindrone Acetate/Ethinyl Estradiol 24 Days
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
Study: NCT00932321
Drug: Norethindrone Acetate /Ethinyl Estradiol 21 Days
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
Study: NCT02775916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03057015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
Study: NCT03057015
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
Study: NCT02623699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT01469273
Drug: Mutaflor® Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of Mutaflor-Suspension on 10 consecutive days.
Study: NCT03114020
Drug: Placebo Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day 3 ml of placebo inhalation solution
Study: NCT01119950
Drug: NVA237 12.5 µg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Study: NCT01119950
Drug: NVA237 25.0 µg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Study: NCT01119950
Drug: NVA237 12.5 µg twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
Study: NCT01119950
Drug: NVA237 50.0 µg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Study: NCT01119950
Drug: NVA237 25.0 µg twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
Study: NCT01119950
Drug: NVA237 100.0 µg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Study: NCT01119950
Drug: NVA237 50.0 µg twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
Study: NCT01119950
Drug: Placebo to NVA237 once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Study: NCT01675518
Drug: ASP7991
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01675518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00479336
Drug: OPC-41061 7.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg, 1 tablet a day
Study: NCT00479336
Drug: OPC-41061 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 1 tablet a day
Study: NCT00479336
Drug: OPC-41061 15mg
Normalized name: naphazoline hydrochloride 0.27 MG/ML / pheniramine maleate 3.15 MG/ML [Opcon-A]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg, 1 tablet a day
Study: NCT02655380
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
Study: NCT00362206
Drug: Fenofibrate/Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fenofibrate and Simvastatin 20mg
Study: NCT00362206
Drug: Fenofibrate/Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fenofibrate and Simvastatin 40 mg
Study: NCT00362206
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40 mg
Study: NCT00057382
Drug: T138067 intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00057382
Drug: doxorubicin intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00541697
Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00345202
Drug: HMG-CoA reductase inhibition (atorvastatin)
Normalized name: HMG CoA reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00762463
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule, 200 mg QD, 6-12 weeks
Study: NCT03355846
Drug: Proctocella
Approvals — FDA: no, EMA: no, PMDA: no
Description: after hygiene treatment for 4 weeks;
Study: NCT03355846
Drug: Flavonil® cps
Approvals — FDA: no, EMA: no, PMDA: no
Description: after meals twice a day for 15 days
Study: NCT03355846
Drug: Flavonil® Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment for 4 weeks;~.
Study: NCT03038295
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.
Study: NCT02610582
Drug: rAAV.hCNGA3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subretinal injection of rAAV.hCNGA3
Study: NCT01568749
Drug: Paracetamol formulation 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol
Study: NCT02930343
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
Study: NCT02930343
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
Study: NCT02930343
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
Study: NCT01552018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 tablet per day for 3 months.
Study: NCT01951560
Drug: Isotonic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: By infusion over 1 hour
Study: NCT03721432
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule given 60 minutes prior to epidural anesthesia
Study: NCT03015974
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03015974
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03015974
Drug: ACE Inhibitor or Angiotensin receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05395949
Drug: conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
Study: NCT01137799
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (single dose)
Study: NCT02186574
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01702558
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered at de-escalating doses (starting from 750 mg/m\^2) to determine the MTD.
Study: NCT01702558
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered at the MTD determined in Cohort 1.
Study: NCT00962637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily
Study: NCT03400826
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.
Study: NCT03400826
Drug: Placebo 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
Study: NCT00335400
Drug: Anesthetic Dilating Gel
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02533908
Drug: Fentanyl intranasal
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
Study: NCT02533908
Drug: NaCl 0.9% intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
Study: NCT00981682
Drug: SER120
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day treatment of nocturia
Study: NCT01922739
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Study: NCT02575235
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group takes the placebo for the same period.
Study: NCT01922739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
Study: NCT01526317
Drug: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
Study: NCT03299452
Drug: Non Chemotherapy
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
Study: NCT00755495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
Study: NCT02518971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule daily
Study: NCT02346175
Drug: SHR3824
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02346175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01440088
Drug: TH-302 in Combination with Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.~Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302.
Study: NCT01440088
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.
Study: NCT03299452
Drug: Chemotherapy and target therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
Study: NCT03299452
Drug: Chinese herb medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
Study: NCT01616069
Drug: epinephrine and levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
Study: NCT01978496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo